These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Symposium on levodopa in Parkinson's disease. Clinical and pharmacological aspects. Where do we go from here? Clin Pharmacol Ther; 1971; 12(2):408-16. PubMed ID: 5577487 [No Abstract] [Full Text] [Related]
26. [L-dopa in Parkinson's syndrome]. Filho RM; de Karam GM Rev Bras Med; 1971 May; 28(5):220-31. PubMed ID: 5563096 [No Abstract] [Full Text] [Related]
27. Reappraisal of levodopa therapy for Parkinson's disease. A three-year experience with outpatients in private practice. McFarland HR Mo Med; 1974 Sep; 71(9):535-7. PubMed ID: 4854038 [No Abstract] [Full Text] [Related]
28. [Treatment of parkinsonism with L-dopa]. Court J; Kase JC; Palacios E; Mena I Rev Med Chil; 1971 Jun; 99(6):399-401. PubMed ID: 5561157 [No Abstract] [Full Text] [Related]
29. [Our first observations on Parkinson's disease or parkinsonian syndromes treated with L-dopa]. Boudouresques J; Khalil R; Vigouroux RA; Gosset A; Daniel F; Dufour H Mars Med; 1971; 108(2):85-9. PubMed ID: 5548385 [No Abstract] [Full Text] [Related]
31. Levodopa and physical therapy in treatment of patients with Parkinson's disease. Stern PH; McDowell F; Miller JM; Robinson M Arch Phys Med Rehabil; 1970 May; 51(5):273-7. PubMed ID: 5420013 [No Abstract] [Full Text] [Related]
32. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature. Lewis I J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008 [No Abstract] [Full Text] [Related]
33. [Recent advances and pharmacological basis of the medical treatment of Parkinson's syndrome]. Shibazaki H Shinkei Kenkyu No Shimpo; 1971; 15(4):992-1002. PubMed ID: 4400830 [No Abstract] [Full Text] [Related]
34. Quantitative measurements of L-dopa therapy in Parkinson's disease. Webster DD Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483 [No Abstract] [Full Text] [Related]
35. [Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease]. Buscaino GA; Campanella G Sist Nerv; 1970; 22(2):82-91. PubMed ID: 5504561 [No Abstract] [Full Text] [Related]
36. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)]. Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970 [No Abstract] [Full Text] [Related]
37. [Preliminary observations on the use of intravenous amantadine and of the association of oral amantadine with anticholinergic drugs and with levo-dopa in the treatment of Parkinson's disease]. Fasano VA; Urciuoli R; Broggi G Minerva Med; 1970 Jul; 61(53):2895-903. PubMed ID: 5428170 [No Abstract] [Full Text] [Related]
38. [Treatment of Parkinson's disease by L-DOPA]. Barbeau A Union Med Can; 1969 Feb; 98(2):183-6. PubMed ID: 5773394 [No Abstract] [Full Text] [Related]
39. [L-dopa in the treatment of Parkinson's disease]. Völler G Med Welt; 1970 Jul; 27():1267-8. PubMed ID: 5512643 [No Abstract] [Full Text] [Related]
40. Progress in the treatment of Parkinson's disease. Kelly R J R Nav Med Serv; 1969; 55(1):26-34. PubMed ID: 5775493 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]